Kornimate/medical-research-clean huggingface dataset:
heart health now (previously known as fast pace nc)

Conditions: Cardiovascular Disease

Summary: the objective of this study is to determine if primary care practice support accelerates the dissemination and implementation of patient-centered outcome results (pcor) findings to improve heart health and increases primary care practices' capacity to incorporate other pcor findings in the future.

the burden of cardiovascular disease in north carolina remains large. the latest data available show an annual cardiovascular death rate of 263 per 100,000 explaining almost one-third of deaths in the state. disease progression is largely determined by several risk factors including elevated blood pressure or cholesterol, not using aspirin for prevention, and tobacco use. primary care practices as currently organized have been unable to get more than half these patients to achieve recommended targets for risk factor reduction. small independent practices, in particular, lack resources for enhanced practice support to improve cardiovascular care. this study will enroll 300 primary care practices to evaluate the effect of primary care support on evidence-based cardiovascular disease (cvd) prevention and organizational change process measures. each practice will start the trial as a control, receive the intervention at a randomized time point, and then enter a maintenance period 12 months after starting the intervention. all practices will receive 12 months of the intense intervention including onsite quality improvement (qi) facilitation, academic detailing, electronic health record (ehr) support, and, through the north carolina health information exchange (hie), a shared statewide utility providing whole population analytics, care gap identification, benchmarking, and an external reporting mechanism which otherwise would not be available to independent practices. a successful intervention would prove that practice facilitation supported by effective informatics tools is an effective method of translating pcor findings into practice. discernible reductions in cardiovascular risk in 300 practices covering over an estimated 900,000 adult patients would likely lead to prevention of thousands of cardiovascular events within 10 years.

Eligibility criteria:
inclusion criteria: * primary care practice in north carolina with 10 or fewer providers in a single location * must have implemented an ehr and either be connected to or have agreed to connect to the hie. exclusion criteria: * practices with more than 10 providers in a single location * practices receiving practice facilitation services beyond the usual support provided by area health education centers (ahec) or the community care of north carolina (ccnc) program through their parent organization. * practices without an ehr * practices where the central practice organization either bars the practice from our program or provides onsite facilitation services equal to or greater than the 4-6 hour standard contact with a qi coach
short and medium-term effects of manual therapy on latent myofascial pain

Conditions: Latent Myofascial Trigger Point of Upper Trapezius Muscle

Summary: the purpose of this study was to investigate the short and medium-term effects of three manual techniques on cervical range of motion and pressure pain sensitivity in subjects with mechanical stress, presenting latent trigger point of upper trapezius muscle.

myofascial pain syndrome is a common non-articular musculoskeletal chronic pain which has not been yet fully understood. it is characterized by myofascial trigger point. this trigger point is clinically classified as active or latent. some studies have demonstrated the potential relevance of latent trigger point. in fact, its presence may cause muscle activation pattern alterations, increase nociceptive sensitivity and cause sympathetic activity alterations. nevertheless, the vast majority of individuals, even asymptomatic, have latent trigger point. high prevalence of myofascial trigger points subsists at cervical and scapular regions. there is few data regarding myofascial trigger point physiopathology. furthermore, a diversity of therapeutic interventions consisting of trigger point inactivation and interruption of the vicious cycle is suggested in literature. nevertheless, the effectiveness of these different interventions in trigger points and the duration of the effects are not yet fully clarified.

Eligibility criteria:
inclusion criteria: * volunteers with 18 or more years of age * with a palpable latent trigger point in the fibbers of the upper trapezius muscle * with an average time of computer work of at least 2h/day. exclusion criteria: * with a body mass index (bmi) equal or higher than 31 kg/cm2 * with bilateral latent triggers in the fibers of the upper trapezius muscle * have done any pharmacological therapeutic during any of the 7 days before the study or anti-coagulant therapeutics * have done any treatment at cervical region during the month before the study * having cardio-respiratory, neurological, neuro-musculoskeletal, oncologic or systemic pathologies * having cognitive deficits or psychologic/psychiatric disturbances * be pregnant * having a clinical history of cervical, high dorsal, shoulder or cranial surgery or trauma during the prior 12 months.

Keywords: manual therapy trigger point range of motion pain threshold pain perception
effects of butyrate against pediatric obesity

Conditions: Obesity, Childhood

Summary: worldwide obesity is a public health concern that is defined by the world health organization as abnormal or excessive fat accumulation that may impair health. the main drivers of obesity pathogenesis seem to be a long-term of energy discrepancy between too many calories consumed and an increase of sedentary behavior. a growing body of evidence suggests that the set of microbes that live within the digestive tract, making up the gut microbiota (gm), play a metabolic role in energy regulation and substrate metabolism. various factors can impact gm, one of these are dietary compounds that deeply affect the growth and metabolism of gut bacteria, since fermentation of nutrients is one core function of the intestinal microbes. among fermentation products an array of small organic metabolites are short-chain fatty acids (scfas) acetate, propionate and butyrate. among scfas, the c-4 fatty acid butyrate, the main fuel for the colonocytes, might have a potential in alleviating obesity and related metabolic complications. butyrate could act as a regulator of body weight: a reasonable speculation is that butyrate acts on components of the energy balance, promoting energy expenditure and/or reducing energy intake. preclinical studies have shown that butyrate supplementation prevent high-fat diet-induced obesity and it is able to treat obesity. with the sharp increase of obesity prevalence seen in the pediatric population, novel insights are necessary to counteract this epidemic disease, the outcome of the study is to see whether oral butyrate supplementation could exert similar effect in obese children.


Eligibility criteria:
inclusion criteria: * children/adolescents with diagnosis of obesity (bmi \>95° percentile for age and sex) observed at pediatric section of department of translational medical sciences (university of naples federico ii) exclusion criteria * age at enrollment \ 17 years * bmi \<95° percentile for age and sex * patients under pharmacological treatment for obesity (metformin) * patients assuming vitamin e, * patients assuming pre-, pro- or synbiotics * simultaneous presence of other chronic diseases unrelated to obesity: * cancer, * immunodeficiency, * cystic fibrosis, * allergies, * celiac disease, * autoimmune diseases, * neuropsychiatric disorders, * type 1 diabetes, * inflammatory bowel diseases, * malformations of urinary or gastrointestinal or respiratory tract, * chronic lung diseases, genetic and metabolic diseases, * chronic hematological diseases. * history of surgery for the treatment of obesity * any medical condition that may interfere with participation in this study * participation in other clinical trials still in progress
safety, pharmacokinetics and pharmacodynamics of bms-936559 in severe sepsis

Conditions: Severe Sepsis; Septic Shock

Summary: the purpose of this study is to determine whether bms-936559 is safe and has the desired pharmacologic activity in patients who have severe sepsis.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * severe sepsis or septic shock for at least 24 hours * documented or suspected infection * sepsis-induced immunosuppression * men and women ≥ 18 years old exclusion criteria: * autoimmune disease * organ transplant or bone marrow transplant * cancer treated in the past 6 months * hepatitis b virus (hbv) infection * human immunodeficiency virus (hiv) infection and not on therapy prior to this episode of sepsis * hepatitis c virus (hcv) infection and still has virus (not cured)
investigation of efficacy and safety of electrical signal therapy provided by dr biolyse® device in covid-19 disease

Conditions: COVID-19 Pneumonia; Virus Diseases; COVID-19

Summary: dr. biolyse® is a device with artificial intelligence that works in sync with the immune system and can be integrated like an element of this system. it is designed to develop chemical immunity within the body against infections. it gives electrical signals to the body without causing any pain and suffering to the patient. the electric current it applies is of a type that is not used in homes, and it is the frequency feature of direct current. the aim of this study is to evaluate the safety and efficacy of the biolyse device. for minimizing the use of drugs in covid-19 patients and treating drug-related organ damage during treatment we hope that by conducting this study, we will obtain sufficient data to obtain approval (ce certification) for routine use and marketing of this medical device in patients. once this happens, we will be able to ensure that this device is accessible/usable for patients suffering from similar diseases, especially covid-19, regardless of any studies.


Eligibility criteria:
inclusion criteria: * men and women between the ages of 18-65 * patients with mild moderate complicated or uncomplicated covid 19 pneumonias * those who accept to be followed up and treated as an inpatient * those who have at least one laboratory and clinical finding that can be evaluated during follow-up exclusion criteria: * patients with severe course or covid 19 pneumonia requiring intensive care follow-up * pregnant or breastfeeding women * epilepsy, arrhythmia, dementia, heart failure, severe lung disease, patients with active malignancy and those with pacemaker * "vulnerable population" patients defined in icu

Keywords: electrification signal therapy dr.biolyse
faith and community in action: increasing awareness and management of depression in african american communities

Conditions: Depression; Awareness; Self-management

Summary: specific aims/study objectives: 1. evaluate acceptability and implementation of the "oh happy day: still i rise class," which comprise a one-time 4-hour class in which participants will learn about depression with the goal of increasing knowledge of depression and self-management of depression with use of a guided class and self-help workbook. measures of acceptability will include class attendance, completion of workbook activities and satisfaction. measures of implementation will include satisfaction, class enrollment, fidelity in delivery of class content, and cost analysis. 2) evaluate participants' knowledge of depression pre-and immediate post-class, and 3-months post class. measure: depression quiz. the investigators hypothesize participants will show increased knowledge of depression pre -and post-class. 3) examine effectiveness of the oh happy day class- still i rise (ohdc-sir) in prevention of depression and 3- months' post- class. measure, patient health questionnaire - ( phq-9) 4) examine effectiveness of ohdc-sir in reducing symptoms of depression 3- months' post- class. measure, phq-9. the investigators hypothesize the ohdc-sir will result in reduction in depressive symptoms 3- months' post-class.

major depressive disorder (mdd) is a major public health concern and is quickly approaching the status of a global public health crisis. according to the world health organization, by 2020 mdd will be the leading cause of disability globally. in the us an estimated 9.0% of adults report symptoms for current mdd (i.e., during the preceding 2 weeks). it is well documented that women (4.0%) are significantly more likely to report and be diagnosed with mdd compared to men (2.7%) nimh, 20017). in addition, health disparities research examining mdd show african americans evidence higher prevalence of depression (4.0%) compared to whites (3.1%) and african americans report more chronic mdd and associated disability than do whites (56.5% vs. 38.6%; williams et al., 2007). despite being burdened by mdd, african americans evidences low seeking of professional help. however, they highly rely on religious coping. this, it is important to work in partnership with african american clergy and african americans in community based research to create programs that are more aligned with their cultural and religious beliefs. investigators propose using a one-group (ohdc-sir) non-randomized observational trial and a sample of 100 african american men and women participants (age 25 and older) with measures at baseline, immediately at the end of the class, and 3- months' post-class. the total duration of the study is 4 months.

Eligibility criteria:
inclusion criteria: * african american male or female * age 25 and older * residence in the state of wisconsin * with or without depression exclusion criteria: * self-report of a psychotic disorder such as * schizophrenia * bipolar disorder * cognitive disorder such as dementia * presently experiencing suicidal ideations.
effect of weight loss and lactation (the eva-trial)

Conditions: Cardiovascular Risk Factor

Summary: a randomized controlled trial aiming to investigate the effects and possible interactions of diet induced weight loss and lactation on cardiometabolic profile


Eligibility criteria:
inclusion criteria: * pregnant women in gestational week \<32, with a pre-pregnant bmi 25-35 kg/m2 * residence in oslo/bærum and surrounding area * intention to breastfeed their child * able to read and write in norwegian. exclusion criteria: * medication that influences lipid or glucose metabolism * chronic disease that influences lipid or glucose metabolism (e.g. diabetes (world health organization, who, 2006) or diabetes in pregnancy (who 2013)) * premature birth (before week 36) * preeclampsia * previous breast reducing surgery
safety of a new type of treatment called gene transfer for the treatment of severe hemophilia b

Conditions: Hemophilia B

Summary: in this study a modified virus called adeno-associated virus (aav) will be used to transfer a normal gene for human clotting factor ix into patients with severe hemophilia b (aav human factor ix vector). gene therapy is a very new medical technique being used in a number of clinical studies for diseases such as cancer and cystic fibrosis. at this time, the u.s. food and drug administration has approved no gene transfer products for commercial use. to date, 8 subjects have received aav vector in the muscle for a hemophilia b trial by intramuscular injection, and, to date, 6 subjects have been treated with aav vector in the current hemophilia b liver trial. eleven cystic fibrosis subjects have received aav vector into their nasal sinuses or lungs to date. in this study, aav human factor ix vector will be injected into the liver using a catheter inserted into a large blood vessel (called the proper hepatic artery or the right hepatic artery).


Eligibility criteria:
* males with severe hemophilia b with factor ix activity level \< 1% of normal. * life expectancy of \> 1 year. * age \> 18 years old. * ability to give informed consent. * greater than twenty exposure days of treatment with factor ix protein. * no history or presence of an inhibitor to factor ix protein. * subjects must be able to receive factor ix protein on a home infusion protocol. * subjects must have a normal protime (pt). * hepatitis c infected subjects will be evaluated for liver fibrosis based on liver biopsy data graded on a scale of 0-4 (poynard et. al., 1997). subjects who are hepatitis c antibody and rna positive and have not had a liver biopsy within the last 36 months will be required to have one. * subjects must have low aav titer.

Keywords: hemophilia b factor ix gene transfer adeno-associated virus (aav)
targeting worry to improve sleep

Conditions: Anxiety; Sleep Disturbance

Summary: the purpose of this study is to test an app-based mindfulness training program for worry to see if it can help individuals decrease worry and improve sleep.

in this study, 80 individuals with worry interfering with sleep will be randomized to receive unwinding anxiety or to treatment as usual (50/50 chance). the active intervention period will last 2 months, with an optional 2-month follow-up period in which the intervention remains available. changes in mindfulness, emotional reactivity, cognition and sleep behavior at specified time points will be measured. the primary engagement targets will be non-reactivity and worry. the primary behavioral outcome target will be sleep.

Eligibility criteria:
inclusion criteria: * score \> 40 on the penn state worry questionnaire (pswq) * score ≥ to 40% on worry interfering with sleep scale (wiss) * owns a smartphone * willing to wear a sleep tracker for at least 1 week exclusion criteria: * any usage of psychotropic medication: not on a stable dosage 6+ weeks * medical disorder of the severity that would interfere with ability to attend visits and complete study milestones * use of benzodiazepine or hypnotic sleep aid on as needed (i.e. prn) * known sleep disorder * psychotic disorder * post-traumatic stress disorder * severe depression (score \> 3 on phq-2) * current shift work employment * bmi \> 35 * evening caffeine use * pregnant women

Keywords: worry
effectiveness of a decision support system in improving the diagnosis and screening rate of breast cancer

Conditions: Breast Cancer

Summary: clinical decision support has been shown to improve the performance of screening tests; however, few studies have documented direct clinical benefit resulting from the increased screening promoted by clinical decision support systems. the purpose of this study was to determine if a standards-based, sophisticated decision support system could not only promote additional breast cancer screening, but also detect significantly more breast cancer

breast cancer is the most common female cancer. in the united states, the second most common cause of cancer death in women, and the main cause of death in women ages 45 to 55 years old. the u.s. preventive services task force recommends screening mammography, with or without clinical breast examination, every one to two years among women aged 50 to 69 years old. recent research has shown that health care delivered in industrialized nations often falls short of optimal, evidence based care. us adults receive only about half of recommended care. to address these deficiencies in care, health-care organizations are increasingly turning to clinical decision support systems. a clinical decision-support system is any computer program designed to help health-care professionals to make clinical decisions. in a sense, any computer system that deals with clinical data or knowledge is intended to provide decision support. examples include manual or computer based systems that attach care reminders to the charts of patients needing specific preventive care services and computerized physician order entry systems that provide patient-specific recommendations as part of the order entry process. such systems have been shown to improve prescribing practices, reduce serious medication errors, enhance the delivery of preventive care services, and improve adherence to recommended care standards. the aim of this study is to show the efficacy of a decision-support system as a strategy for improving the performance of the mammography care process and the detection of significantly more breast cancer.

Eligibility criteria:
inclusion criteria: * women between 50 and 69 years old exclusion criteria: * breast neoplasms * bilateral mastectomy * disabled persons

Keywords: decision support techniques electronic health records reminder systems early detection of cancer mammography women
papsy - memory in psychiatry

Conditions: Cognitive Impairment

Summary: memory in psychiatry project (papsy) aims to map the distribution and severity of cognitive impairment in patients of outpatient psychiatric offices across the geographical area of the czech republic. 1000 patients in 90 psychiatric offices will undergo cognitive tests (alba and picnir) and psychometric scales (sfaq-cz and gds-cz) to asses their functional state and depressive symptoms. if applicable, caretakers will also be asked about the extent of the participant's autonomy and behavioral impairment (using ofaq-cz and mbi-c-cz scales). the trial's primary goal is to assess the distribution of cognitive impairment among diagnostic groups in psychiatric care according to the icd-10. additionally, the feasibility of alba and picnir methods to uncover previously undiagnosed cognitive impairments will be evaluated.


Eligibility criteria:
inclusion criteria: * dispensarization of at least six months in an outpatient psychiatric office with an icd-10 diagnosis * age\>=45 * permanent residency in the geographical area of the czech republic exclusion criteria: * diagnosis of mental retardation (f70-f79) according to icd-10 * refusal to sign the informed consent and consent with gdpr * uncorrected visual impairment * uncorrected auditory impairment * inability to participate in the project

Keywords: cognitive impairment outpatient psychiatric service population distribution